Targeting VEGF-A in myeloid cells enhances natural killer cell responses to chemotherapy and ameliorates cachexia

Nature Communications

Volumn 7, Issue , 2016, Pages

  Klose, Ralph ^a   Krzywinska, Ewelina ^a   Castells, Magali ^a   Gotthardt, Dagmar ^b   Putz, Eva Maria ^b   Kantari Mimoun, Chahrazade ^a   Chikdene, Naima ^a   Meinecke, Anna Katharina ^a   Schrödter, Katrin ^c   Helfrich, Iris ^c   Fandrey, Joachim ^c   Sexl, Veronika ^b   Stockmann, Christian ^a  

^a INSERM   (France)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMERIN; CHEMOATTRACTANT; CISPLATIN; ETOPOSIDE; FATTY ACID; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTRALIZING ANTIBODY; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN A; ANTINEOPLASTIC AGENT; CHEMERIN PROTEIN, MOUSE; CHEMOKINE; SIGNAL PEPTIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE;

CANCER; CAUSE OF DEATH; CELLS AND CELL COMPONENTS; CHEMOTHERAPY; GENETIC ANALYSIS; IMMUNE RESPONSE; INHIBITOR; MUSCLE; SENESCENCE; TUMOR; WEIGHT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATGL GENE; BONE MARROW CELL; CACHEXIA; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL AGING; CELL MIGRATION; CELL SIZE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG TARGETING; ENDOTHELIUM; GASTROCNEMIUS MUSCLE; GENE EXPRESSION; GENE INACTIVATION; HSL GENE; IMMUNE RESPONSE; IMMUNOREACTIVITY; LIPOLYSIS; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; MUSCLE ATROPHY; MUSCLE CELL; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR CELL; TUMOR VASCULARIZATION; TUMOR VOLUME; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; COMPLICATION; DRUG SCREENING; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; NEOPLASM; PATHOLOGY; TRANSGENIC MOUSE;

ADIPOSE TISSUE, WHITE; ANIMALS; ANTINEOPLASTIC AGENTS; CACHEXIA; CHEMOKINES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KILLER CELLS, NATURAL; LIPOLYSIS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUSCLE, SKELETAL; MYELOID CELLS; NEOPLASMS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84983249423     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12528     Document Type: Article

References (41)

1. Zitvogel, L., Kepp, O. & Kroemer, G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat. Rev. Clin. Oncol. 8, 151-160 (2011).
2. Carmeliet, P. & Jain, R. K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 10, 417-427 (2011).
3. Stockmann, C. et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456, 814-818 (2008).
4. Fearon, K. C. & Moses, A. G. Cancer cachexia. Int. J. Cardiol. 85, 73-81 (2002).
5. DeWys, W. D. Nutritional care of the cancer patient. JAMA 244, 374-376 (1980).
6. Deans, C. & Wigmore, S. J. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr. Opin. Clin. Nutr. Metab. Care 8, 265-269 (2005).
7. Lainscak, M., Filippatos, G. S., Gheorghiade, M., Fonarow, G. C. & Anker, S. D. Cachexia: common, deadly, with an urgent need for precise definition and new therapies. Am. J. Cardiol. 101, 8E-10E (2008).
8. Das, S. K. et al. Adipose triglyceride lipase contributes to cancer-Associated cachexia. Science 333, 233-238 (2011).
9. Bing, C. et al. Zinc-Alpha2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proc. Natl Acad. Sci. USA 101, 2500-2505 (2004).
10. Argiles, J. M., Busquets, S., Toledo, M. & Lopez-Soriano, F. J. The role of cytokines in cancer cachexia. Curr. Opin. Support. Palliat. Care 3, 263-268 (2009).
11. Fearon, K. C., Glass, D. J. & Guttridge, D. C. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 16, 153-166 (2012).
12. Fearon, K., Arends, J. & Baracos, V. Understanding the mechanisms and treatment options in cancer cachexia. Nat. Rev. Clin. Oncol. 10, 90-99 (2013).
13. Roh, S. G. et al. Chemerin-A new adipokine that modulates adipogenesis via its own receptor. Biochem. Biophys. Res. Commun. 362, 1013-1018 (2007).
14. Zabel, B. A., Silverio, A. M. & Butcher, E. C. Chemokine-like receptor 1 expression and chemerin-directed chemotaxis distinguish plasmacytoid from myeloid dendritic cells in human blood. J. Immunol. 174, 244-251 (2005).
15. Wittamer, V. et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J. Exp. Med. 198, 977-985 (2003).
16. Parolini, S. et al. The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood 109, 3625-3632 (2007).
17. Zitvogel, L., Tesniere, A. & Kroemer, G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6, 715-727 (2006).
18. Putz, E. M. et al. CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. Cell Rep. 4, 437-444 (2013).
19. Pachynski, R. K. et al. The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses. J. Exp. Med. 209, 1427-1435 (2012).
20. Kerbel, R. S. & Kamen, B. A. The anti-Angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 4, 423-436 (2004).
21. Schmitt, C. A. et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109, 335-346 (2002).
22. Ben-Porath, I. & Weinberg, R. A. The signals and pathways activating cellular senescence. Int. J. Biochem. Cell Biol. 37, 961-976 (2005).
23. Chien, Y. et al. Control of the senescence-Associated secretory phenotype by NF-kappaB promotes senescence and enhances chemosensitivity. Genes Dev. 25, 2125-2136 (2011).
24. Xue, W. et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656-660 (2007).
25. Krizhanovsky, V. et al. Senescence of activated stellate cells limits liver fibrosis. Cell 134, 657-667 (2008).
26. Acosta, J. C. et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133, 1006-1018 (2008).
27. Vacchelli, E. et al. Trial Watch: Immunostimulatory cytokines. Oncoimmunology 2, e24850 (2013).
28. Dranoff, G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 4, 11-22 (2004).
29. Muruganandan, S. et al. Chemerin, a novel peroxisome proliferator-Activated receptor gamma (PPARgamma) target gene that promotes mesenchymal stem cell adipogenesis. J. Biol. Chem. 286, 23982-23995 (2011).
30. Shimamura, K. et al. Identification of a stable chemerin analog with potent activity toward ChemR23. Peptides 30, 1529-1538 (2009).
31. Issa, M. E. et al. Chemokine-like receptor 1 regulates skeletal muscle cell myogenesis. Am. J. Physiol. Cell Physiol. 302, C1621-C1631 (2012).
32. Xie, Q. et al. Chemerin-induced mitochondrial dysfunction in skeletal muscle. J. Cell. Mol. Med. 19, 986-995 (2015).
33. Welford, S. M. & Giaccia, A. J. Hypoxia and senescence: The impact of oxygenation on tumor suppression. Mol. Cancer Res. 9, 538-544 (2011).
34. Nizet, V. & Johnson, R. S. Interdependence of hypoxic and innate immune responses. Nat. Rev. Immunol. 9, 609-617 (2009).
35. Tartour, E. et al. Angiogenesis and immunity: A bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev. 30, 83-95 (2011).
36. Cervi, D. et al. Enhanced natural-killer cell and erythropoietic activities in VEGF-A-overexpressing mice delay F-MuLV-induced erythroleukemia. Blood 109, 2139-2146 (2007).
37. Bruno, A. et al. The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer. Neoplasia 15, 133-142 (2013).
38. Hansen, W. et al. Neuropilin 1 deficiency on CD4Foxp3 regulatory T cells impairs mouse melanoma growth. J. Exp. Med. 209, 2001-2016 (2012).
39. Obeid, M. et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54-61 (2007).
40. Gerber, H. P. et al. VEGF is required for growth and survival in neonatal mice. Development 126, 1149-1159 (1999).
41. Clausen, B. E., Burkhardt, C., Reith, W., Renkawitz, R. & Forster, I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 8, 265-277 (1999).